These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 29514841)

  • 1. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
    Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
    Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
    [No Abstract]   [Full Text] [Related]  

  • 2. Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer.
    Yang Y; Qu A; Zhao R; Hua M; Zhang X; Dong Z; Zheng G; Pan H; Wang H; Yang X; Zhang Y
    Mol Oncol; 2018 Dec; 12(12):2072-2084. PubMed ID: 30242969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High expression of miR-181c as a predictive marker of recurrence in stage II colorectal cancer.
    Yamazaki N; Koga Y; Taniguchi H; Kojima M; Kanemitsu Y; Saito N; Matsumura Y
    Oncotarget; 2017 Jan; 8(4):6970-6983. PubMed ID: 28036302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer.
    Low YS; Blöcker C; McPherson JR; Tang SA; Cheng YY; Wong JYS; Chua C; Lim TKH; Tang CL; Chew MH; Tan P; Tan IB; Rozen SG; Cheah PY
    Cancer Lett; 2017 Sep; 403():13-20. PubMed ID: 28624625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
    Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
    Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma.
    Liu N; Cui RX; Sun Y; Guo R; Mao YP; Tang LL; Jiang W; Liu X; Cheng YK; He QM; Cho WC; Liu LZ; Li L; Ma J
    Int J Cancer; 2014 Mar; 134(6):1359-68. PubMed ID: 23999999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRT17 as a prognostic biomarker for stage II colorectal cancer.
    Ujiie D; Okayama H; Saito K; Ashizawa M; Thar Min AK; Endo E; Kase K; Yamada L; Kikuchi T; Hanayama H; Fujita S; Sakamoto W; Endo H; Saito M; Mimura K; Saze Z; Momma T; Ohki S; Kono K
    Carcinogenesis; 2020 Jul; 41(5):591-599. PubMed ID: 31754689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer.
    Miyoshi J; Toden S; Yoshida K; Toiyama Y; Alberts SR; Kusunoki M; Sinicrope FA; Goel A
    Sci Rep; 2017 Mar; 7():43393. PubMed ID: 28262692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients.
    Ji D; Qiao M; Yao Y; Li M; Chen H; Dong Q; Jia J; Cui X; Li Z; Xia J; Gu J
    EBioMedicine; 2018 Sep; 35():189-197. PubMed ID: 30166271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.
    Manceau G; Imbeaud S; Thiébaut R; Liébaert F; Fontaine K; Rousseau F; Génin B; Le Corre D; Didelot A; Vincent M; Bachet JB; Chibaudel B; Bouché O; Landi B; Bibeau F; Leroy K; Penault-Llorca F; Van Laethem JL; Demetter P; Tejpar S; Rossi S; Mosakhani N; Osterlund P; Ristamäki R; Sarhadi V; Knuutila S; Boige V; André T; Laurent-Puig P
    Clin Cancer Res; 2014 Jun; 20(12):3338-47. PubMed ID: 24771647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Exosomal MicroRNA-21 as a Biomarker in Each Tumor Stage of Colorectal Cancer.
    Tsukamoto M; Iinuma H; Yagi T; Matsuda K; Hashiguchi Y
    Oncology; 2017; 92(6):360-370. PubMed ID: 28376502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer.
    Imaoka H; Toiyama Y; Fujikawa H; Hiro J; Saigusa S; Tanaka K; Inoue Y; Mohri Y; Mori T; Kato T; Toden S; Goel A; Kusunoki M
    Ann Oncol; 2016 Oct; 27(10):1879-86. PubMed ID: 27502702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer.
    Matsuyama T; Kandimalla R; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kinugasa Y; Hansen TF; Fakih M; Uetake H; Győrffy B; Goel A
    Int J Cancer; 2020 Dec; 147(11):3250-3261. PubMed ID: 32657428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
    Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
    Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection.
    Hess J; Unger K; Maihoefer C; Schüttrumpf L; Wintergerst L; Heider T; Weber P; Marschner S; Braselmann H; Samaga D; Kuger S; Pflugradt U; Baumeister P; Walch A; Woischke C; Kirchner T; Werner M; Werner K; Baumann M; Budach V; Combs SE; Debus J; Grosu AL; Krause M; Linge A; Rödel C; Stuschke M; Zips D; Zitzelsberger H; Ganswindt U; Henke M; Belka C
    Clin Cancer Res; 2019 Mar; 25(5):1505-1516. PubMed ID: 30171046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer.
    Toiyama Y; Hur K; Tanaka K; Inoue Y; Kusunoki M; Boland CR; Goel A
    Ann Surg; 2014 Apr; 259(4):735-43. PubMed ID: 23982750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
    Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
    Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Multiple miRNA-Based Signatures for Predicting Overall Survival and Recurrence-Free Survival of Colorectal Cancer Patients.
    Qian J; Zeng L; Jiang X; Zhang Z; Luo X
    Med Sci Monit; 2019 Sep; 25():7258-7271. PubMed ID: 31560680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated expression of miR-24-3p is a potentially adverse prognostic factor in colorectal adenocarcinoma.
    Kerimis D; Kontos CK; Christodoulou S; Papadopoulos IN; Scorilas A
    Clin Biochem; 2017 Apr; 50(6):285-292. PubMed ID: 27939727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer.
    Matsuyama T; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kawano T; Uetake H; Goel A
    Mol Cancer; 2019 Feb; 18(1):19. PubMed ID: 30717807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.